Aptorum Group Ltd. (APM)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Andean Precious Metals: Record-High Gold-Silver Prices Pave The Way For A Mid-Tier Producer
Andean Precious Metals Corp. (APM:CA) is rated a Buy, driven by strong financials and robust growth strategies in gold and silver production. APM:CA benefits from rising precious metal prices, solid free cash flow, and a healthy balance sheet, supporting ongoing expansion and share buybacks. San Bartolomé's long-term ore agreement and Golden Queen's exploration program underpin production growth and extended mine life for APM:CA.
Aptorum Group Ltd. (APM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aptorum Group Ltd. ever had a stock split?
Aptorum Group Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Chung Yuen Huen CEO | NASDAQ (CM) Exchange | G6096M106 CUSIP |
| GB Country | 1 Employees | - Last Dividend | 23 Jan 2023 Last Split | - IPO Date |
Overview
Aptorum Group Limited is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products aimed at treating a range of diseases, primarily in oncology and infectious diseases. The company, incorporated in 2010 and headquartered in London, United Kingdom, operates through its subsidiaries under two segments: Therapeutics and Non-Therapeutics. Originally known as APTUS Holdings Limited, it rebranded to Aptorum Group Limited in October 2017. Aptorum Group's engagement in therapeutic and diagnostic projects spans across various other disease areas including neurology, gastroenterology, and metabolic disorders, leveraging on its systematic screening of approved drug molecules and microbiome-based research platforms.
Products and Services
- SACT-1
Designed for the treatment of neuroblastoma and other cancer types, SACT-1 represents the company's foray into oncology therapeutics.
- SACT-COV19
This product is in development for addressing the coronavirus disease, showcasing Aptorum Group's response to infectious disease outbreaks.
- ALS-4
ALS-4 is aimed at treating bacterial infections caused by Staphylococcus aureus, including methicillin-resistant strains (MRSA), highlighting the company's commitment to combating antibiotic-resistant bacteria.
- ALS-1
Targeted at viral infections, ALS-1 is being developed to treat influenza virus A infections, reinforcing the company's focus on infectious diseases.
- ALS-2/3
These two products are being developed for the treatment of Gram-positive bacterial infections, expanding the company's antibacterial portfolio.
- RPIDD
A pathogen molecular diagnostic project, RPIDD stands as a testament to Aptorum Group's dedication to advancing diagnostic capabilities alongside therapeutic solutions.
- NativusWell DOI (NLS-2)
A dietary supplement, NLS-2 underlines Aptorum Group’s interests in non-therapeutic offerings aimed at general wellness and metabolic disease prevention.
- NLS-1
For the treatment of endometriosis, NLS-1 underscores the company's attention to women's health and reproductive diseases.
- DLS-1+2
These products are geared towards treating non-small cell lung cancer (NSCLC) with specific mutations, highlighting Aptorum Group’s investment in targeted cancer therapies.
- DLS-3
An autoimmune small molecule, indicating the company's exploration into treatments for autoimmune disorders.
- CLS-1
Focused on the treatment of obesity, CLS-1 represents Aptorum Group’s venture into metabolic disorders beyond diabetes and lipid anomalies.
